Ignite Creation Date:
2024-05-06 @ 7:53 PM
Last Modification Date:
2024-10-26 @ 3:16 PM
Study NCT ID:
NCT06176885
Status:
RECRUITING
Last Update Posted:
2023-12-27
First Post:
2023-12-09
Brief Title:
Efficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite Stable MSS Initially Unresectable Metastatic Colorectal Cancer
Sponsor:
yue junhan
Organization:
Jinhua Central Hospital
Study Overview
Official Title:
Efficacy and Safety of Camrelizumab Combined With Irinotecan Leucovorin and Fluorouracil FOLFIRI Chemotherapy and Bevacizumab Targeted Induction Therapy in the First-line Treatment of Microsatellite Stable MSS Initially Unresectable Metastatic Colorectal Cancer a Prospective Multicenter Single-arm Study
Status:
RECRUITING
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
FOBECAMS
Brief Summary:
The goal of this clinical trial is to explore the feasibility of a new mode of chemotherapy and bevacizumab induction therapy combined with immunotherapy as first-line treatment for patients with initially unresectable metastatic colorectal cancer MSS The main questions it aims to answer are
1 To explore the efficacy and safety of this treatment mode
2 Try to study treatment benefit the characteristics of the crowd Participants will combined with immunotherapy after chemotherapy and bevacizumab induction therapy
1 To explore the efficacy and safety of this treatment mode
2 Try to study treatment benefit the characteristics of the crowd Participants will combined with immunotherapy after chemotherapy and bevacizumab induction therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None